Dosimetric Planning Comparison for Left Ventricle Avoidance in Non-small Cell Lung Cancer Radiotherapy.

INTRODUCTION

Radiation may unintentionally injure myocardial tissue, potentially leading to radiation-induced cardiac disease (RICD), with the net benefit of non-small cell lung cancer (NSCLC) radiotherapy (RT) due to the proximity of the lung and heart. RTOG-0617 showed a greater reduction in overall survival (OS) comparing higher doses to standard radiation doses in NSCLC RT. V5GyHeart has been reported as an OS predictor in the first- and fifth-year follow-ups. A worsening OS trend was reported in another study where the mean left ventricle dose (mean LV) was ≥14.5 Gy. It is therefore important to spare the heart, specifically the LV, from radiation. Furthermore, dose-limiting factors toward the normal lung should be accounted for to prevent radiation-induced lung injury.

METHODS

The LV and left anterior descending artery (LAD) were also contoured on the average four-dimensional computed tomography (4D-CT) dataset that contained clinically defined targets and normal structures for stage III NSCLC RT. The prescribed treatment plans (n=15) were retrospectively optimized with the clinical goals of minimizing the mean LV and mean heart dose while maintaining the dose constraint of V20GyLung ≤30% and V95%PTV ≥95%. Dose-volume histograms were used to compare the heart and lung dosimetric parameters between the delivered and reoptimized RT plans.

RESULTS

A significant reduction (p≤0.044) was observed in the mean LV, mean heart dose, mean LAD dose, max LAD dose, and V5GyHeart from the reoptimized RT plans. V20GyLung ≤30% and V95%PTV ≥95% were maintained, and no differences were observed in the mean lung, V5GyLung, V20GyLung, mean esophagus, and max cord.

CONCLUSION

Minimizing the LV dose in NSCLC RT plans is achievable and dosimetrically advantageous for the heart while maintaining dose constraints to the normal lung and maximizing tumor control. Radiation dose reduction to cardiac substructures may decrease the RICD risk in NSCLC patients.